Evolocumab in Patients With High-Risk Diabetes: Results From the VESALIUS-CV Trial
In high-risk diabetes without prior heart attack or stroke, evolocumab lowered major cardiovascular events when added to usual cholesterol treatment.
*Prespecified subgroup analysis of randomized trial; Level 2 (OCEBM).
Citation
Leiter LA, Giugliano RP, Marston NA, et al. Evolocumab in Patients With High-Risk Diabetes: Results From the VESALIUS-CV Trial. Diabetes Care. 2026;49(8):1366-1373. doi:10.2337/dc26-0847
Background
People with diabetes have higher cardiovascular risk, and lowering low-density lipoprotein cholesterol reduces that risk. This study tested whether adding evolocumab helps prevent first major cardiovascular events in a particularly high-risk diabetes population.
Patients
6,002 adults with high-risk diabetes, defined by small-vessel disease, chronic insulin use, or diabetes duration of at least 10 years. Important exclusions included prior heart attack or stroke.
Intervention
Evolocumab 140 mg injected every 2 weeks, added to optimized cholesterol-lowering therapy.
Control
Matching placebo injection every 2 weeks, added to optimized cholesterol-lowering therapy.
Outcome
Two main composite outcomes: coronary heart disease death, heart attack, or ischemic stroke; and the same outcome plus artery-opening procedures for poor blood flow.
Follow-up Period
Median 4.6 years.
Results
| Outcome | Evolocumab | Placebo | Effect | NNT |
|---|---|---|---|---|
| Main 3-part composite (primary) | 6.1% | 8.4% | HR 0.71 (95% CI, 0.59-0.86) | 44 |
| Main 4-part composite (primary) | 11.7% | 14.5% | HR 0.79 (95% CI, 0.69-0.91) | 36 |
| All-cause death | 8.8% | 11.0% | HR 0.79 (95% CI, 0.67-0.93) | 46 |
| Ischemic stroke | 2.0% | 3.1% | HR 0.66 (95% CI, 0.48-0.91) | 91 |
HR = hazard ratio; CI = confidence interval; NNT = number needed to treat over 4.6 years.
Analyses were intention-to-treat. This was not a non-inferiority trial. The control reflected usual optimized cholesterol treatment without evolocumab.
Limitations
This was a subgroup analysis, although prespecified. The “high-risk diabetes” definition may not match all guidelines. About one-third already had atherosclerosis, limiting generalizability. Hemoglobin A1c and diabetes complications during follow-up were not measured. Industry funding and author employment by the manufacturer raise bias concerns.
Funding
Amgen funded; several authors employed by Amgen.
Clinical Application
Consider evolocumab for selected high-risk diabetes patients with persistent elevated cholesterol despite optimized therapy, especially when preventing first cardiovascular events is a priority.
Discussion
Sign in to join the discussion.
In this prespecified subgroup analysis of a randomized placebo-controlled trial, evolocumab reduced 3P-MACE in high-risk diabetes from 8.4% to 6.1% (HR 0.71). How should we weigh the trial’s internal validity, subgroup nature, absolute benefit, cost, and applicability before changing LDL-C targets? In this randomized trial subgroup, the HR for 3P-MACE with evolocumab versus placebo was 0.71, with event rates of 6.1% vs 8.4%. Which interpretation is most accurate?